All Title Author
Keywords Abstract

From Health Advice to Taboo: Community Perspectives on the Treatment of Sleeping Sickness in the Democratic Republic of Congo, a Qualitative Study

DOI: 10.1371/journal.pntd.0003686

Full-Text   Cite this paper   Add to My Lib


Background Socio-cultural and economic factors constitute real barriers for uptake of screening and treatment of Human African Trypanosomiasis (HAT) in the Democratic Republic of Congo (DRC). Better understanding and addressing these barriers may enhance the effectiveness of HAT control. Methods We performed a qualitative study consisting of semi-structured interviews and focus group discussions in the Bandundu and Kasa? Oriental provinces, two provinces lagging behind in the HAT elimination effort. Our study population included current and former HAT patients, as well as healthcare providers and program managers of the national HAT control program. All interviews and discussions were voice recorded on a digital device and data were analysed with the ATLAS.ti software. Findings Health workers and community members quoted a number of prohibitions that have to be respected for six months after HAT treatment: no work, no sexual intercourse, no hot food, not walking in the sun. Violating these restrictions is believed to cause serious, and sometimes deadly, complications. These strong prohibitions are well-known by the community and lead some people to avoid HAT screening campaigns, for fear of having to observe such taboos in case of diagnosis. Discussion The restrictions originally aimed to mitigate the severe adverse effects of the melarsoprol regimen, but are not evidence-based and became obsolete with the new safer drugs. Correct health information regarding HAT treatment is essential. Health providers should address the perspective of the community in a constant dialogue to keep abreast of unintended transformations of meaning.


[1]  Boelaert M, Meheus F, Robays J, Lutumba P. Socio-economic aspects of neglected diseases: sleeping sickness and visceral leishmaniasis. Ann Trop Med Parasitol. 2010; 104: 535–542. doi: 10.1179/136485910X12786389891641. pmid:21092391
[2]  Rimoin AW&HPJ . NTDs in the heart of darkness: the Democratic Republic of Congo's unknown burden of neglected tropical diseases. PLoS Negl Trop Dis. 2013;7 (7) e2118. doi: 10.1371/journal.pntd.0002118. pmid:23936557
[3]  Yansouni CP, Bottieau E, Lutumba P, Winkler AS, Lynen L, Buscher P et al. Rapid diagnostic tests for neurological infections in central Africa. Lancet Infect Dis. 2013; 13: 546–558. doi: 10.1016/S1473-3099(13)70004-5. pmid:23623369
[4]  World Health Organization. Control and surveillance of human African trypanosomiasis: report of a WHO Expert committee. Geneva, 2013,WHO technical report series; no. 984.
[5]  Blum J, Schmid C, Burri C. Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop. 2006; 97: 55–64. pmid:16157286 doi: 10.1016/j.actatropica.2005.08.001
[6]  Barrett MP. Problems for the chemotherapy of human African trypanosomiasis. Curr Opin Infect Dis. 2000; 13: 647–651. pmid:11964836 doi: 10.1097/00001432-200012000-00012
[7]  Barrett MP, Boykin DW, Brun R, Tidwell RR. Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br J Pharmacol. 2007; 152: 1155–1171. pmid:17618313 doi: 10.1038/sj.bjp.0707354
[8]  Priotto G, Fogg C, Balasegaram M, Erphas O, Louga A, Checchi F et al. Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clin Trials. 2006; 1: e39. pmid:17160135 doi: 10.1371/journal.pctr.0010039
[9]  World Health Organization. Control and surveillance of African trypanosomiasis. Geneva, 1998, WHO Technical Report, Series 881.
[10]  Simarro PP, Franco J, Diarra A, Postigo JA, Jannin J. Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis. Parasitology. 2012; 139: 842–846. doi: 10.1017/S0031182012000169. pmid:22309684
[11]  Robays J, Lefevre P, Lutumba P, Lubanza S, Kande Betu KM V, Van der Stuyft P et al. Drug toxicity and cost as barriers to community participation in HAT control in the Democratic Republic of Congo. Trop Med Int Health. 2007; 12: 290–298. pmid:17300638 doi: 10.1111/j.1365-3156.2006.01768.x
[12]  Mpanya A, Hendrickx D, Vuna M, Kanyinda A, Lumbala C, Tshilombo V et al. Should I get screened for sleeping sickness? A qualitative study in Kasai province, Democratic Republic of Congo. PLoS Negl Trop Dis. 2012; 6: e1467. doi: 10.1371/journal.pntd.0001467. pmid:22272367
[13]  Robays J, Bilengue MM, Van der Stuyft P, Boelaert M. The effectiveness of active population screening and treatment for sleeping sickness control in the Democratic Republic of Congo. Trop Med Int Health. 2004; 9: 542–550. pmid:15117297 doi: 10.1111/j.1365-3156.2004.01240.x
[14]  Hasker E, Lutumba P, Chappuis F, Kande V, Potet J, De Weggheleire A et al. Human African trypanosomiasis in the Democratic Republic of the Congo: a looming emergency? PLoS Negl Trop Dis. 2012; 6: e1950. doi: 10.1371/journal.pntd.0001950. pmid:23272260
[15]  Saldana J. The Coding Manual for Qualitative Researchers. 2nd ed. London, SAGE publication Ltd, 2013.
[16]  Burke J. La trypanosomiase Humaine Africaine. Ministère des affaires étrangères, du commerce extérieur et de la coopération au développement; administration générale de la coopération au développement, d / 1976 /1290 /2.
[17]  Robays J, Nyamowala G, Sese C, Betu Ku MK V, Lutumba P, Van der Stuyft P et al. High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo. Emerg Infect Dis. 2008; 14: 966–967. doi: 10.3201/eid1406.071266. pmid:18507916
[18]  Hasker E, Mpanya A, Makabuza J, Mbo F, Lumbala C, Kumpel J et al. Treatment outcomes for human African Trypanosomiasis in the Democratic Republic of the Congo: analysis of routine program data from the world's largest sleeping sickness control program. Trop Med Int Health. 2012; 17: 1127–1132. doi: 10.1111/j.1365-3156.2012.03042.x. pmid:22809002
[19]  Bailey EJ. Medical Anthropology and African American Health. Westport: Bergin & Garvey. 2000; 270 p.
[20]  Beardsworth A KT. Sociology on the Menu: An Invitation to the Study of Food and Society. London, 1997. Routledge 288.
[21]  Manderson L. Hot-cold food and medical theories: overview and introduction. Soc Sci Med. 1987; 25, (4) 329–330. pmid:3686084 doi: 10.1016/0277-9536(87)90270-x
[22]  Lutumba P, Makieya E, Shaw A, Meheus F, Boelaert M. Human African trypanosomiasis in a rural community, Democratic Republic of Congo. Emerg Infect Dis. 2007; 13: 248–254. pmid:17479887 doi: 10.3201/eid1302.060075
[23]  Burri C. Chemotherapy against human African trypanosomiasis: is there a road to success? Parasitology. 2010; 137: 1987–1994. doi: 10.1017/S0031182010001137. pmid:20961469
[24]  Chappuis F, Udayraj N, Stietenroth K, Meussen A, Bovier PA. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Clin Infect Dis. 2005; 41: 748–751. pmid:16080099 doi: 10.1086/432576
[25]  Priotto G, Pinoges L, Fursa IB, Burke B, Nicolay N, Grillet G et al. Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. BMJ. 2008; 336: 705–708. doi: 10.1136/bmj.39485.592674.BE. pmid:18321960
[26]  Pepin J, Tetreault L, Gervais C. [The use of oral corticosteroids in the treatment of human African trypanosomiasis: a retrospective survey in Nioki, Zaire]. Ann Soc Belg Med Trop. 1985; 65: 17–29. pmid:4004371
[27]  Pepin J, Milord F. The treatment of human African trypanosomiasis. Adv Parasitol. 1994; 33: 1–47. pmid:8122565 doi: 10.1016/s0065-308x(08)60410-8
[28]  Franco JR, Simarro P, Diarra A, Ruiz-Postigo JA, Samo M et Jannin JG. Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage human African trypanosomiasis. Research and Reports in Tropical Medicine. 2012; 13:1–9. doi: 10.2147/rrtm.s34399
[29]  Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet. 2009; 374: 56–64. doi: 10.1016/S0140-6736(09)61117-X. pmid:19559476
[30]  Haller L, Adams H, Merouze F, Dago A. Clinical and pathological aspects of human African trypanosomiasis (T. b. gambiense) with particular reference to reactive arsenical encephalopathy. Am J Trop Med Hyg. 1986; 35: 94–99. pmid:3946740
[31]  Gouteux JP, Malonga JR (1985) [Socio-entomologic survey in human trypanosomiasis focus of Yamba (Peoples Republic of Congo)]. Med Trop. 1985; 45: 259–263. pmid:4068972
[32]  Uranw S, Ostyn B, Dorlo TP, Hasker E, Dujardin B, Dujardin JC et al. Adherence to miltefosine treatment for visceral leishmaniasis under routine conditions in Nepal. Trop Med Int Health. 2013; 18: 179–187. doi: 10.1111/tmi.12025. pmid:23199340
[33]  Manne JM, Snively CS, Ramsely JM, Salgado MO, Bamighausen T, Reich MR et al. Barriers to Treatment Access for Chagas Disease in Mexico. PLoS Negl Trop Dis. 2013; 7(10): e2488. doi: 10.1371/journal.pntd.0002488. pmid:24147169


comments powered by Disqus